Four Decades for Justice
Cravath’s broad‑based intellectual property practice has deep experience advising clients ranging from early‑stage startups to global companies in corporate contexts across the full spectrum of intellectual property disciplines, technologies and jurisdictions. Our corporate IP practice is distinctive for its “cross‑disciplinary and highly collaborative approach,” placing Cravath “a class apart” for providing “integrated solutions to the most pressing legal and business problems faced by industry leaders.” (IAM Patent 1000)
Cravath’s IP lawyers work hand in glove with our premier corporate practices to handle the many intellectual property issues that arise in complex transactions, including issues relating to patents, trademarks, copyrights, data, trade secrets, privacy and information security. We also advise on matters in connection with emerging technologies, including artificial intelligence and fintech solutions involving Web3/blockchain, digital assets, smart contracts and decentralized networks.
Our IP lawyers bring a great depth of technical and scientific backgrounds to provide expert advice related to:
Cravath also provides strategic counseling, review and analysis in developing and managing intellectual property portfolios, commercializing innovation‑based assets and optimizing intellectual property rights to ensure our clients are maximizing value from their intellectual property in the U.S. and in non-U.S. markets.
Cravath helps clients navigate AI and data issues with respect to data ownership and licensing, business operations and disputes related to AI and data, as well as the acquisition of data and AI technologies. Our expertise across subject areas allows us to provide interdisciplinary advice on AI and data issues, including ownership of and rights to use AI algorithms and related data, confidentiality management and related transaction structuring.
Cravath advises on a wide variety of data security and privacy issues across the whole spectrum of transactions and projects, including data collection, data storage, multi‑party data arrangements and agreements, such as between data controllers and/or data processors, cross‑border data sharing, protection of personally identifiable and other sensitive information, and privacy and data protection compliance matters, including advising on privacy policies and privacy notices and other privacy compliance requirements under the GDPR and other relevant regimes.
Cravath’s IP lawyers work hand in glove with our premier corporate practices to handle the many intellectual property issues that arise in complex transactions, including issues relating to patents, trademarks, copyrights, data, trade secrets, privacy and information security. We also advise on matters in connection with emerging technologies, including artificial intelligence and fintech solutions involving Web3/blockchain, digital assets, smart contracts and decentralized networks.
Our IP lawyers bring a great depth of technical and scientific backgrounds to provide expert advice related to:
Cravath also provides strategic counseling, review and analysis in developing and managing intellectual property portfolios, commercializing innovation‑based assets and optimizing intellectual property rights to ensure our clients are maximizing value from their intellectual property in the U.S. and in non-U.S. markets.
Cravath helps clients navigate AI and data issues with respect to data ownership and licensing, business operations and disputes related to AI and data, as well as the acquisition of data and AI technologies. Our expertise across subject areas allows us to provide interdisciplinary advice on AI and data issues, including ownership of and rights to use AI algorithms and related data, confidentiality management and related transaction structuring.
Cravath advises on a wide variety of data security and privacy issues across the whole spectrum of transactions and projects, including data collection, data storage, multi‑party data arrangements and agreements, such as between data controllers and/or data processors, cross‑border data sharing, protection of personally identifiable and other sensitive information, and privacy and data protection compliance matters, including advising on privacy policies and privacy notices and other privacy compliance requirements under the GDPR and other relevant regimes.
Deals & Cases
April 02, 2024
Cravath represented the underwriters in connection with the $1 billion registered senior notes offering of Dell International L.L.C. and EMC Corporation. Dell International L.L.C. and EMC Corporation are wholly owned subsidiaries of Dell Technologies, a leading integrated technology solutions provider in the IT industry. The transaction closed on March 18, 2024.
Deals & Cases
April 02, 2024
On April 2, 2024, Endeavor Group Holdings, Inc. (“Endeavor”), a global sports and entertainment company, announced that it has entered into a definitive agreement to be acquired by Silver Lake, the global leader in technology investing, in partnership with the Endeavor management team and additional anchor investors. Cravath is representing the independent Special Committee of Endeavor’s board of directors in connection with the transaction.
Deals & Cases
March 22, 2024
On March 21, 2024, ECN Capital Corp. (“ECN Capital”), a leading provider of business services to North American based banks, credit unions, life insurance companies, pension funds and institutional investors, announced the sale of Red Oak Inventory Finance (“Red Oak”) to BharCap Partners, a private investment firm. The transaction closed on February 21, 2024. Cravath represented ECN Capital in connection with the transaction.
Deals & Cases
February 28, 2024
On February 28, 2024, Viatris Inc. (“Viatris”), a global healthcare company, and Idorsia Ltd (“Idorsia”) announced they have entered into agreements for a significant global research and development collaboration under which Viatris will receive exclusive global development and commercialization rights to two Phase 3 assets as well as the potential to add additional innovative assets in the future.
Deals & Cases
February 12, 2024
On February 12, 2024, CymaBay Therapeutics (“CymaBay”) and Gilead Sciences, Inc. (“Gilead”) announced a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of CymaBay’s investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis, complements Gilead’s existing liver portfolio and aligns with its longstanding commitment to bringing transformational medicines to patients. Cravath is representing CymaBay in connection with the transaction.
Activities & Publications
April 22, 2024
On April 18, 2024, Law360 published an article written by Cravath partners David J. Kappos and Sasha Rosenthal‑Larrea entitled “Surveying Legislative Trends as States Rush to Regulate AI.” The article discusses trends in the large quantity of state artificial intelligence legislation introduced in 2024 thus far, including the imposition of obligations on AI developers and deployers; the required disclosure of the use of generative AI; the regulation of specific uses of AI such as its use in litigation; and the regulation of the risk of algorithmic discrimination.
Activities & Publications
April 19, 2024
Cravath of counsel Kathryn-Ann Stamm participated in the African Women Entrepreneurship Cooperative’s 2024 General Assembly, which was held from April 17‑19, 2024, in Gaborone, Botswana. The event convened women entrepreneurs and business leaders, experts and executives from across the globe to discuss how to build partnerships and the value of collaboration in entrepreneurship. Kathryn‑Ann led a multi‑day learning lab entitled “The Elements of Win‑Win Partnerships,” which equipped attendees with an in‑depth roadmap to prepare, create and nurture mutually beneficial partnerships for their businesses. Through the learning lab, Kathryn‑Ann provided attendees with a comprehensive toolkit, empowering them to successfully navigate the lifecycle of partnerships while effectively protecting their own business interests and intellectual property.
Activities & Publications
April 12, 2024
On April 8, 2024, Cravath partner David J. Kappos participated in the Best Practices in Intellectual Property 10th Annual Conference, which was hosted by Intellectual Property Resources in Tel Aviv and featured global decision-makers and leading IP professionals to discuss global IP issues, trends and legislation. Dave served as one of the program’s chairs and delivered opening remarks. He also spoke on two panels entitled “Top-Line Issues in Intellectual Property — An Exchange Among Former IP Office Heads” and “Assessing Congressional Engagement with the U.S. IP System — A First-Ever Congressional Member-Level Scorecard,” respectively, and moderated a panel entitled “AI Management for the AI Era Policy and Practice.”
Activities & Publications
April 05, 2024
Cravath partner David J. Kappos and of counsel Christopher Davis participated in the 31st Annual Intellectual Property Law & Policy Conference, which was hosted by Fordham Law School from April 4‑5, 2024 in New York. Dave delivered a presentation entitled “The U.S. IP System Is Under Siege,” which reviewed the IP atmosphere in the U.S., including COVID vaccine IP waivers; COVID therapeutic and diagnostic waivers; accusations of “evergreening” and “patent thickets” in the biopharma area; and standard essential patent rate-setting by the European Union Intellectual Property Office. Chris spoke on a panel entitled “U.S. Copyright Developments,” which examined the future of fair use in light of Andy Warhol Foundation v. Goldsmith, the progress of the Copyright Claims Board and more.
Activities & Publications
April 02, 2024
In April 2024, Cravath continued its “Tech Explainers” series, which introduces and explains technical, cutting‑edge concepts and describes their importance in a way that is accessible to and easily understood by business and legal professionals outside the technical community.
Deals & Cases
April 02, 2024
Cravath represented the underwriters in connection with the $1 billion registered senior notes offering of Dell International L.L.C. and EMC Corporation. Dell International L.L.C. and EMC Corporation are wholly owned subsidiaries of Dell Technologies, a leading integrated technology solutions provider in the IT industry. The transaction closed on March 18, 2024.
Deals & Cases
April 02, 2024
On April 2, 2024, Endeavor Group Holdings, Inc. (“Endeavor”), a global sports and entertainment company, announced that it has entered into a definitive agreement to be acquired by Silver Lake, the global leader in technology investing, in partnership with the Endeavor management team and additional anchor investors. Cravath is representing the independent Special Committee of Endeavor’s board of directors in connection with the transaction.
Deals & Cases
March 22, 2024
On March 21, 2024, ECN Capital Corp. (“ECN Capital”), a leading provider of business services to North American based banks, credit unions, life insurance companies, pension funds and institutional investors, announced the sale of Red Oak Inventory Finance (“Red Oak”) to BharCap Partners, a private investment firm. The transaction closed on February 21, 2024. Cravath represented ECN Capital in connection with the transaction.
Deals & Cases
February 28, 2024
On February 28, 2024, Viatris Inc. (“Viatris”), a global healthcare company, and Idorsia Ltd (“Idorsia”) announced they have entered into agreements for a significant global research and development collaboration under which Viatris will receive exclusive global development and commercialization rights to two Phase 3 assets as well as the potential to add additional innovative assets in the future.
Deals & Cases
February 12, 2024
On February 12, 2024, CymaBay Therapeutics (“CymaBay”) and Gilead Sciences, Inc. (“Gilead”) announced a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of CymaBay’s investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis, complements Gilead’s existing liver portfolio and aligns with its longstanding commitment to bringing transformational medicines to patients. Cravath is representing CymaBay in connection with the transaction.
Activities & Publications
April 22, 2024
On April 18, 2024, Law360 published an article written by Cravath partners David J. Kappos and Sasha Rosenthal‑Larrea entitled “Surveying Legislative Trends as States Rush to Regulate AI.” The article discusses trends in the large quantity of state artificial intelligence legislation introduced in 2024 thus far, including the imposition of obligations on AI developers and deployers; the required disclosure of the use of generative AI; the regulation of specific uses of AI such as its use in litigation; and the regulation of the risk of algorithmic discrimination.
Activities & Publications
April 19, 2024
Cravath of counsel Kathryn-Ann Stamm participated in the African Women Entrepreneurship Cooperative’s 2024 General Assembly, which was held from April 17‑19, 2024, in Gaborone, Botswana. The event convened women entrepreneurs and business leaders, experts and executives from across the globe to discuss how to build partnerships and the value of collaboration in entrepreneurship. Kathryn‑Ann led a multi‑day learning lab entitled “The Elements of Win‑Win Partnerships,” which equipped attendees with an in‑depth roadmap to prepare, create and nurture mutually beneficial partnerships for their businesses. Through the learning lab, Kathryn‑Ann provided attendees with a comprehensive toolkit, empowering them to successfully navigate the lifecycle of partnerships while effectively protecting their own business interests and intellectual property.
Activities & Publications
April 12, 2024
On April 8, 2024, Cravath partner David J. Kappos participated in the Best Practices in Intellectual Property 10th Annual Conference, which was hosted by Intellectual Property Resources in Tel Aviv and featured global decision-makers and leading IP professionals to discuss global IP issues, trends and legislation. Dave served as one of the program’s chairs and delivered opening remarks. He also spoke on two panels entitled “Top-Line Issues in Intellectual Property — An Exchange Among Former IP Office Heads” and “Assessing Congressional Engagement with the U.S. IP System — A First-Ever Congressional Member-Level Scorecard,” respectively, and moderated a panel entitled “AI Management for the AI Era Policy and Practice.”
Activities & Publications
April 05, 2024
Cravath partner David J. Kappos and of counsel Christopher Davis participated in the 31st Annual Intellectual Property Law & Policy Conference, which was hosted by Fordham Law School from April 4‑5, 2024 in New York. Dave delivered a presentation entitled “The U.S. IP System Is Under Siege,” which reviewed the IP atmosphere in the U.S., including COVID vaccine IP waivers; COVID therapeutic and diagnostic waivers; accusations of “evergreening” and “patent thickets” in the biopharma area; and standard essential patent rate-setting by the European Union Intellectual Property Office. Chris spoke on a panel entitled “U.S. Copyright Developments,” which examined the future of fair use in light of Andy Warhol Foundation v. Goldsmith, the progress of the Copyright Claims Board and more.
Activities & Publications
April 02, 2024
In April 2024, Cravath continued its “Tech Explainers” series, which introduces and explains technical, cutting‑edge concepts and describes their importance in a way that is accessible to and easily understood by business and legal professionals outside the technical community.
Explore
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2024 Cravath, Swaine & Moore LLP.